Xeris Biopharma Holdings, Inc. XERS Recorlev — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net?
- Xeris Biopharma Holdings, Inc. (XERS) reported recorlev — product revenue, net of $49.77M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s recorlev — product revenue, net increased by 94.9% year-over-year, from $25.53M to $49.77M.
- What does recorlev — product revenue, net mean?
- This metric represents the total net sales generated from the commercialization of a specific pharmaceutical product after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of the product's market adoption, commercial traction, and contribution to the company's overall top-line growth within its therapeutic focus area. Tracking this figure allows investors to evaluate the success of the product's launch trajectory and its ability to capture market share in its respective indication.